SLC9A3 and coronary artery disorder: The results identified the unique-bottlenecks (unique-bottleneck refers to a node that is both a unique node and a bottleneck) FGG and SLC9A3 as the targets of DSS in the treatment of CHD, which were also potential targets for new drug design.